Multiple sclerosis (MS) is an acquired chronic immune-mediated inflammatory condition of the central nervous system (CNS), affecting both the brain and spinal cord. It is estimated that there are over 100,000 patients with MS in the UK. 1 MS is a progressive and debilitating condition with long-term impacts on patients and healthcare resources.
A systematic HES coding search identified 187 patients via ICD and OPCS codes and patterns of hospital attendance. Attendances were collated for the period from 6 months pre-and 6 months post-natalizumab initiation. We defined NHS resource use as hospital activity consisting of the following: number of planned and unplanned hospital visits, planned and unplanned bed days, and outpatient appointments.
Utilising a 12-month observation window, running from 6-months pre-and postnatalizumab initiation, a larger sample size was obtained compared with a 24-month window (i.e. +/-12 months natalizumab initiation). This time interval was clinically relevant because treatment is assessed for evidence of therapeutic benefit after a minimum 6 months. 4 Statistical Analysis: Paired 2-sample t-test for means and 2-sample t-test assuming unequal variances to calculate statistical significance (P<0.05) and descriptive statistics with 95% confidence intervals. 
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To evaluate the impact of natalizumab on NHS (UK National Health Service) resource use from Hospital Episodes Statistics (HES) data.
Hospital activity per patient
Comparing pre-with post-natalizumab periods there was a significant reduction in mean unplanned hospital visits per patient (by 48.12%, p = 0.012). Mean planned hospital visits per patient increased significantly (by 99.35%, p = <0.001). (Table 1 / Figure 1 ).
Mean unplanned bed days per patient reduced by 52.64% whilst planned bed days per patient reduced by 66.74%. However, these figures were not statistically significant (Table 1/ Figure 1) .
Length of hospital visits
The mean duration of an unplanned visit fell slightly from 4.84 bed days to 4.42 bed days (by 8.71%, p=0.580) and the mean duration of a planned visit showed a significant decrease from 0.70 bed days to 0.12 bed days (by 83.32%, p = 0.006) ( Table 2) . The analysis identified that for MS patients, the initiation of natalizumab therapy is associated with a number of changes in hospital activity and NHS resource utilisation. Crucially, there is a significant reduction in unplanned hospital admissions which is likely to be of greatest benefit to patients and the NHS. The reduction in unplanned visits is in line with analyses carried out in this area. 5 However, distinct to previous analyses, there was no associated reduction in outpatient appointments or the mean duration of an unplanned visit. As expected, the number of planned hospital visits increased, due to the regular administration of natalizumab every 28 days.
Further analysis would be recommended using specific hospital-based clinical records in order to ascertain methodological validity and to test model assumptions. Additional work would include identifying other treatments and interventions for which HES is sensitive and specific to particular drugs, therapeutic groups and patient co-morbidities.
The pattern of changes in hospital activity associated with natalizumab support the expected positive clinical outcomes. Confounding aspects were an identification bias in the non-random sampling and the potential for a regression to the mean effect 
